MENU

Translational Medicine

Wafik S. El-Deiry, the deputy cancer center director for translational research and co-program leader in developmental therapeutics at Fox Chase, is an international leader in translational research and one of 40 active American Cancer Society Research professors.Wafik S. El-Deiry, the deputy cancer center director for translational research and co-program leader in developmental therapeutics at Fox Chase, is an international leader in translational research and one of 40 active American Cancer Society Research professors.

 

Vision

The vision of the translational medicine effort at Fox Chase is to discover and bring to patients new diagnostic and prognostic biomarkers, as well as devices and therapeutics, to positively impact the lives of people at risk of cancer as well as patients with cancer.

In order to increase the focus on translational science at Fox Chase Cancer Center, Wafik El-Deiry was recruited in 2014 as the deputy director for translational research and co-Leader of the molecular therapeutics research program.  Through the realization of his vision and through strategic planning, Fox Chase has increased its focus on translational research in order to more effectively bring basic research discoveries to clinical care.

Goals of translational research at Fox Chase Cancer Center

  • Fostering intra- and inter-programmatic collaborations
  • Prioritizing molecular targets and biomarkers
  • Assisting in the early development of translational research protocols
  • Increasing the number and support of investigator initiated translational clinical trials
  • Increasing the national presence for investigators and their translational research
  • Developing collaborations within the region
  • Increasing multi-investigator translational grant submissions

Features of translational research at Fox Chase

  • Translational Research Disease Groups
  • Annual retreat focused on translational medicine and precision medicine
  • Precision Medicine Steering Committee
  • Translational RFA Awards
  • Industry collaborations with Caris Life Sciences and others
  • Participation and leadership in the national MATCH clinical trial
  • Translational Research Support Resources

Related News

Liquid Biopsy is a Beneficial Complement to Tissue Biopsy in Metastatic Colorectal Cancer

PHILADELPHIA (June 4, 2018) – A new study from Fox Chase Cancer Center shows that liquid biopsy can be a valuable tool in assessing patients’ progress throughout treatment for colorectal cancer. Researchers found that administering the blood test at intervals to search for circulating tumor cells or DNA in conjunction with current diagnostic tests can provide information that will help physicians adjust treatment decisions. 

Keep Reading
2018 ASCO Annual Meeting

Fox Chase Cancer Center Presentations at the ASCO Annual Meeting

PHILADELPHIA (May 24, 2018) – As nearly 40,000 cancer researchers, physicians, and advocates gather in Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting, nearly 20 Fox Chase Cancer Center faculty and students will present their research on a range of topics. 

Keep Reading

Fox Chase Cancer Center Announces 2018 Award Recipients for Translational Clinical Protocol Development

PHILADELPHIA (April 23, 2018) — Fox Chase Cancer Center is pleased to announce the awardees of the request for application (RFA) focused on translational clinical protocol development based on basic and preclinical research results. The grants were open to Fox Chase Cancer Center/Temple University member labs.

Keep Reading
Wafik El-Deiry MD, PhD, FACP

Fox Chase Cancer Center Researchers Uncover ONC201 Immune-oncology Effects

PHILADELPHIA ( [Anchor] March 20, 2018) – The Journal of Clinical Investigation recently published a scientific article describing ONC201’s ability to cause intratumoral accumulation and activation of natural killer (NK) and CD3+ T cells in mouse models and patients. The research is from the laboratory of Wafik El-Deiry MD, PhD, FACP, Scientific Founder of Oncoceutics, and Deputy Cancer Center Director for Translational Research at Fox Chase Cancer Center.

Keep Reading

Related Blog Posts

Wafik El-Deiry, MD, Earns Prestigious Smith Chair in Cancer Research

Fox Chase Cancer Center celebrated the investiture of Wafik S. El-Deiry, MD, PhD, FACP, deputy cancer center director and head of translational research, as the William Wikoff Smith Chair in Cancer Research on November 15, 2016. This particular chair has a history of impact from the work of Kenneth Zaret and Ann Skalka.

Keep Reading

Paving the Way for Personalized Therapy

Fox Chase Cancer Center researchers have identified a way forward for personalized cancer treatments for a wide range of cancers. Their findings can provide new insight into the mechanisms of a small molecule and investigational new drug for cancer called ONC201. The drug not only stimulates a powerful anticancer protein called TRAIL, but also the death receptor for TRAIL (also known as DR5) on tumor cells. This allows TRAIL to specifically kill tumor cells.

Keep Reading

Connect with Fox Chase